✦ LIBER ✦

Late-Breaking Abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study

✍ Scribed by D. Miller; V. Filiaci; G. Fleming; R. Mannel; D. Cohn; T. Matsumoto; K. Tewari; P. DiSilvestro; M. Pearl; R. Zaino

Book ID: 113964120
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 108 KB
Volume: 125
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2012.03.034

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of cisplatin as first-lin

Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study

✍ Jt Thigpen; JA Blessing; H Homesley; WT Creasman; G Sutton 📂 Article 📅 1989 🏛 Elsevier Science 🌐 English ⚖ 136 KB

Phase II trial of clsplatin as first-lin

Phase II trial of clsplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: A gynecologic oncology group study

✍ J.Tate Thigpen; John A. Blessing; Howard Homesley; William T. Creasman; Gregory 📂 Article 📅 1989 🏛 Elsevier Science 🌐 English ⚖ 331 KB

A randomized phase III trial of gemcitab

A randomized phase III trial of gemcitabine+docetaxel+bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma (uLMS): A Gynecologic Oncology Group study

✍ Hensley, M.L.; Miller, A.; O'Malley, D.M.; Mannel, R.S.; Behbakht, K.; Bakkum-Ga 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 110 KB

A randomized phase III trial of paclitax

A randomized phase III trial of paclitaxel with or without bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: Eastern cooperative oncology group trial E2100

✍ R. Zon; Miller; M. Wang; J. Gralow; M. Dickler; M. Cobleigh; E. Perez; T. Shenki 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 129 KB

Phase III randomized clinical trial of c

Phase III randomized clinical trial of cisplatin plus paclitaxel vs the non-platinum chemotherapy doublet of topotecan plus paclitaxel in women with recurrent, persistent, or advanced cervical carcinoma: A Gynecologic Oncology Group study

✍ Tewari, K.; Sill, M.; Monk, B.; Long, H.; Ramondetta, L.; Landrum, L.; Oaknin, A 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 324 KB

RIBBON-1: Randomized, Double-Blind, Plac

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative, Locally Recurrent or Metastatic Breast Cancer

✍ Robert, N. J.; Dieras, V.; Glaspy, J.; Brufsky, A. M.; Bondarenko, I.; Lipatov, 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 317 KB